Late Relapses following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era

The standard of care for diffuse large B cell lymphoma (DLBCL) relapsing after front line therapy is high dose chemotherapy and autologous stem cell transplant (ASCT). Evidence suggests that early relapses (i.e. within 1 year) following this approach portends exceptionally poor outcomes. However, there are limited data examining relapses>1 year after ASCT for patients with refractory or relapsed DLBCL, particularly in the rituximab era. We sought to examine the impact of early ( ≤1 year) and late (>1 year) relapse following ASCT in a single-institution cohort of patients with relapsed and refractory DLBCL treated with chemo-immunotherapy.

Source: Clinical Lymphoma, Myeloma and Leukemia - November 21, 2016 Category: Hematology Authors: Bradley D. Hunter, Megan Herr, Philip J. Meacham, Ferdous Barlaskar, Andrew G. Evans, W. Richard Burack, Jane L. Liesveld, Michael W. Becker, Laurie A. Milner, Louis Constine, Sughosh Dhakal, Paul M. Barr, Jonathan W. Friedberg, Carla Casulo Tags: Original Study Source Type: research